Explore Our Biomarker Menu

Biomarker:

VCAM-1

Biological or Clinical Significance:

Vascular cell adhesion protein 1 also known as vascular cell adhesion molecule 1 (VCAM-1) or cluster of differentiation 106 (CD106) is a protein that in humans is encoded by the VCAM1 gene. VCAM-1 functions as a cell adhesion molecule. The gene product is a cell surface sialoglycoprotein, a type I membrane protein that is a member of the Ig superfamily.

The VCAM-1 protein mediates the adhesion of lymphocytes, monocytes, eosinophils, and basophils to vascular endothelium. It also functions in leukocyte-endothelial cell signal transduction, and it may play a role in the development of atherosclerosis and rheumatoid arthritis. Upregulation of VCAM-1 in endothelial cells by cytokines occurs as a result of increased gene transcription and through stabilization of Messenger RNA. The promoter region of the VCAM-1 gene contains functional tandem NF-κB sites. The sustained expression of VCAM-1 lasts over 24 hours. Primarily, the VCAM-1 protein is an endothelial ligand for VLA-4 (Very Late Antigen-4 or integrin α4β1) of the β1 subfamily of integrins. VCAM-1 expression has also been observed in other cell types. It has also been shown to interact with EZR and Moesin.

References:

Analyte:

VCAM-1

Matrix:

Human Serum and Plasma

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

MSD-ECL

Required Sample Volume

Disease State:

MSD Panel:

Vascular Injury Panel 2 (Human)

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.